The Amylin Pathway Steps Forward as a Distinct Research Frontier

Alongside the multi-agonist race, a separate mechanism is gathering momentum in obesity research: the amylin pathway. The interest is partly about tolerability, with amylin analogs studied for whether they can drive weight loss with a different side-effect profile from established GLP-1 agonists.

The lead data point this year came from petrelintide, a long-acting amylin analog co-developed by Zealand Pharma and Roche. In the Phase 2 ZUPREME-1 trial, petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7% with placebo, while demonstrating placebo-like tolerability. The trial evaluated petrelintide against placebo in 493 people living with overweight and obesity, with a mean baseline BMI of 37.

Tolerability was the headline alongside efficacy. At the maximally effective dose, there were no cases of vomiting and no treatment discontinuations due to gastrointestinal adverse events. Treatment discontinuation due to adverse events was 4.8% in that arm versus 4.9% with placebo, and overall trial withdrawal was 8.4% across petrelintide arms versus 13.6% with placebo.

The weight-loss figure sits below the headline numbers from leading multi-agonist programs, and direct comparison is imprecise across different doses, durations and populations. For context, semaglutide has shown roughly 13 to 15% reductions and tirzepatide around 20% in longer-duration Phase 3 trials. That gap is why some analysts see petrelintide mattering more as a combination component than as a standalone, with Roche building a portfolio rather than betting on a single mechanism.

The development path reflects that thinking. A Phase 2 trial exploring the combination of petrelintide and CT-388 was set to begin in the first half of 2026, and topline results from a second monotherapy trial, ZUPREME-2, in people with type 2 diabetes are expected in the second half of the year.

Petrelintide is investigational. Its safety and efficacy have not been evaluated or approved for marketing by any regulatory authority, and a Phase 3 program is planned to begin later in 2026.

For researchers, the signal is that amylin has matured from a supporting mechanism into a frontier worth tracking on its own terms, both as monotherapy and in combination.

For educational purposes only. This content is informational and reflects publicly reported research developments. It is not medical advice and makes no therapeutic claims. Products referenced are for research use only. Consult a qualified healthcare professional for any medical question.